Third Of Drug Makers Extend Drugs In India Rather Than Make New Ones
This article was originally published in PharmAsia News
Makers of branded drugs are engaged in a trend of extending their drugs rather than launching new ones in India, according to a market study. ORG IMS Health said about a third of brands brought to market each year in India are extensions of existing drugs, and they account for about 18 percent of the value of the domestic market. The study said both multinational companies and local drug makers are engaged in the practice in India. Drugs getting the extensions tend to be those for treating infections, heart problems, dermatology and diabetes, according to the report. (Click here for more
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.